Costing malaria interventions from pilots to elimination programmes.

Comparative cost-effectiveness Cost models Costs IRS MDA Malaria control Malaria elimination Malaria rapid reporting RACD Resource-allocation

Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
14 Sep 2020
Historique:
received: 28 02 2020
accepted: 04 09 2020
entrez: 15 9 2020
pubmed: 16 9 2020
medline: 16 4 2021
Statut: epublish

Résumé

Malaria programmes in countries with low transmission levels require evidence to optimize deployment of current and new tools to reach elimination with limited resources. Recent pilots of elimination strategies in Ethiopia, Senegal, and Zambia produced evidence of their epidemiological impacts and costs. There is a need to generalize these findings to different epidemiological and health systems contexts. Drawing on experience of implementing partners, operational documents and costing studies from these pilots, reference scenarios were defined for rapid reporting (RR), reactive case detection (RACD), mass drug administration (MDA), and in-door residual spraying (IRS). These generalized interventions from their trial implementation to one typical of programmatic delivery. In doing so, resource use due to interventions was isolated from research activities and was related to the pilot setting. Costing models developed around this reference implementation, standardized the scope of resources costed, the valuation of resource use, and the setting in which interventions were evaluated. Sensitivity analyses were used to inform generalizability of the estimates and model assumptions. Populated with local prices and resource use from the pilots, the models yielded an average annual economic cost per capita of $0.18 for RR, $0.75 for RACD, $4.28 for MDA (two rounds), and $1.79 for IRS (one round, 50% households). Intervention design and resource use at service delivery were key drivers of variation in costs of RR, MDA, and RACD. Scale was the most important parameter for IRS. Overall price level was a minor contributor, except for MDA where drugs accounted for 70% of the cost. The analyses showed that at implementation scales comparable to health facility catchment area, systematic correlations between model inputs characterizing implementation and setting produce large gradients in costs. Prospective costing models are powerful tools to explore resource and cost implications of policy alternatives. By formalizing translation of operational data into an estimate of intervention cost, these models provide the methodological infrastructure to strengthen capacity gap for economic evaluation in endemic countries. The value of this approach for decision-making is enhanced when primary cost data collection is designed to enable analysis of the efficiency of operational inputs in relation to features of the trial or the setting, thus facilitating transferability.

Sections du résumé

BACKGROUND BACKGROUND
Malaria programmes in countries with low transmission levels require evidence to optimize deployment of current and new tools to reach elimination with limited resources. Recent pilots of elimination strategies in Ethiopia, Senegal, and Zambia produced evidence of their epidemiological impacts and costs. There is a need to generalize these findings to different epidemiological and health systems contexts.
METHODS METHODS
Drawing on experience of implementing partners, operational documents and costing studies from these pilots, reference scenarios were defined for rapid reporting (RR), reactive case detection (RACD), mass drug administration (MDA), and in-door residual spraying (IRS). These generalized interventions from their trial implementation to one typical of programmatic delivery. In doing so, resource use due to interventions was isolated from research activities and was related to the pilot setting. Costing models developed around this reference implementation, standardized the scope of resources costed, the valuation of resource use, and the setting in which interventions were evaluated. Sensitivity analyses were used to inform generalizability of the estimates and model assumptions.
RESULTS RESULTS
Populated with local prices and resource use from the pilots, the models yielded an average annual economic cost per capita of $0.18 for RR, $0.75 for RACD, $4.28 for MDA (two rounds), and $1.79 for IRS (one round, 50% households). Intervention design and resource use at service delivery were key drivers of variation in costs of RR, MDA, and RACD. Scale was the most important parameter for IRS. Overall price level was a minor contributor, except for MDA where drugs accounted for 70% of the cost. The analyses showed that at implementation scales comparable to health facility catchment area, systematic correlations between model inputs characterizing implementation and setting produce large gradients in costs.
CONCLUSIONS CONCLUSIONS
Prospective costing models are powerful tools to explore resource and cost implications of policy alternatives. By formalizing translation of operational data into an estimate of intervention cost, these models provide the methodological infrastructure to strengthen capacity gap for economic evaluation in endemic countries. The value of this approach for decision-making is enhanced when primary cost data collection is designed to enable analysis of the efficiency of operational inputs in relation to features of the trial or the setting, thus facilitating transferability.

Identifiants

pubmed: 32928227
doi: 10.1186/s12936-020-03405-3
pii: 10.1186/s12936-020-03405-3
pmc: PMC7491157
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

332

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : OPP 1159934
Organisme : Bill and Melinda Gates Foundation
ID : OPP 1159934
Organisme : Bill and Melinda Gates Foundation
ID : OPP 1159934
Organisme : Bill and Melinda Gates Foundation
ID : OPP 1159934
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : PP00P3 170702

Références

Malar J. 2013 Sep 17;12:331
pubmed: 24044506
Malar J. 2016 Aug 15;15(1):412
pubmed: 27527347
Malar J. 2019 Jul 30;18(1):259
pubmed: 31362768
Value Health. 2005 Jan-Feb;8(1):67-79
pubmed: 15841896
Malar J. 2015 May 20;14:211
pubmed: 25985992
Malar J. 2012 Aug 22;11:294
pubmed: 22913727
Lancet. 2013 Sep 7;382(9895):900-11
pubmed: 23594387
Health Policy Plan. 2016 Mar;31(2):205-16
pubmed: 26001813
Trials. 2015 Aug 13;16:347
pubmed: 26268804
Am J Trop Med Hyg. 2015 May;92(5):913-921
pubmed: 25802434
Malar J. 2017 Jun 12;16(1):248
pubmed: 28606143
Value Health. 2015 Mar;18(2):161-72
pubmed: 25773551
Malar J. 2010 Oct 04;9:265
pubmed: 20920328
PLoS Negl Trop Dis. 2007 Oct 31;1(1):e67
pubmed: 17989784
Malar J. 2016 Aug 27;15(1):438
pubmed: 27567642
J Infect Dis. 2016 Dec 15;214(12):1831-1839
pubmed: 27923947
F1000Res. 2017 Aug 29;6:1584
pubmed: 29552335
PLoS Negl Trop Dis. 2016 Dec 5;10(12):e0005037
pubmed: 27918573
BMJ Glob Health. 2017 Sep 25;2(3):e000391
pubmed: 29018584
Malar J. 2011 Oct 21;10:313
pubmed: 22018266
Malar J. 2015 Nov 19;14:465
pubmed: 26586264
Am J Trop Med Hyg. 2010 Sep;83(3):480-8
pubmed: 20810807
Health Econ. 2004 Nov;13(11):1117-24
pubmed: 15386683
Trials. 2017 Nov 2;18(1):511
pubmed: 29096671
Malar J. 2016 Aug 11;15(1):408
pubmed: 27515533
Glob Health Sci Pract. 2016 Dec 28;4(4):529-541
pubmed: 27965266

Auteurs

Katya Galactionova (K)

Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland. e.galactionova@unibas.ch.
University of Basel, Basel, Switzerland. e.galactionova@unibas.ch.

Mar Velarde (M)

Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Kafula Silumbe (K)

Malaria Control and Elimination Partnership in Africa at PATH (MACEPA), Lusaka, Zambia.

John Miller (J)

Malaria Control and Elimination Partnership in Africa at PATH (MACEPA), Lusaka, Zambia.

Anthony McDonnell (A)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Ricardo Aguas (R)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Thomas A Smith (TA)

Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Melissa A Penny (MA)

Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH